Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)
China flag China · Delayed Price · Currency is CNY
10.51
+0.05 (0.48%)
At close: Feb 13, 2026

SHE:002873 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
754.66856.87953.261,087968.7750.18
Other Revenue
0.670.670.730.881.150.76
755.34857.55953.981,088969.84750.95
Revenue Growth (YoY)
-9.99%-10.11%-12.29%12.15%29.15%-2.90%
Cost of Revenue
215.83230.72219.39247.65201.16165.86
Gross Profit
539.51626.83734.59840.02768.69585.09
Selling, General & Admin
469.75513.64589.02673.99606.18474.39
Research & Development
42.7140.4738.1321.5820.3813.3
Other Operating Expenses
13.961210.5413.1713.8111.52
Operating Expenses
523.61568.72637.42709.27642.1498.7
Operating Income
15.958.1197.17130.75126.5886.39
Interest Expense
-10.49-17.57-11.8-10.67-16.6-5.47
Interest & Investment Income
0.440.670.920.731.371.42
Currency Exchange Gain (Loss)
--0---
Other Non Operating Income (Expenses)
1.72-0.051.92-5.41-2.93-2.23
EBT Excluding Unusual Items
7.5741.1688.21115.39108.4280.11
Gain (Loss) on Sale of Investments
-00.02-0.72-0.4--
Gain (Loss) on Sale of Assets
-1.0218.9--0.02-0.1-
Asset Writedown
-2.92-0.71-0.07-0.12-0.37-0.48
Other Unusual Items
5.531.3856.488.694.31
Pretax Income
9.1660.7692.42121.34116.6583.94
Income Tax Expense
1.668.4311.559.8316.049.84
Earnings From Continuing Operations
7.552.3280.87111.52100.6174.1
Net Income
7.552.3280.87111.52100.6174.1
Net Income to Common
7.552.3280.87111.52100.6174.1
Net Income Growth
-86.14%-35.30%-27.48%10.85%35.76%3.75%
Shares Outstanding (Basic)
230220232232227225
Shares Outstanding (Diluted)
230220245244245241
Shares Change (YoY)
-0.98%-9.91%0.41%-0.41%1.34%6.59%
EPS (Basic)
0.030.240.350.480.440.33
EPS (Diluted)
0.030.240.330.460.410.31
EPS Growth
-86.01%-28.18%-27.78%11.30%33.96%-2.66%
Free Cash Flow
107.9926.68-23.92-53.3818.61107.62
Free Cash Flow Per Share
0.470.12-0.10-0.220.080.45
Dividend Per Share
0.0600.1000.0700.1000.0860.061
Dividend Growth
-45.45%42.86%-30.00%16.69%40.03%20.00%
Gross Margin
71.43%73.10%77.00%77.23%79.26%77.91%
Operating Margin
2.10%6.78%10.19%12.02%13.05%11.50%
Profit Margin
0.99%6.10%8.48%10.25%10.37%9.87%
Free Cash Flow Margin
14.30%3.11%-2.51%-4.91%1.92%14.33%
EBITDA
54.9689.14117.51155.38148.33105.47
EBITDA Margin
7.28%10.39%12.32%14.29%15.29%14.04%
D&A For EBITDA
39.0631.0420.3424.6421.7419.09
EBIT
15.958.1197.17130.75126.5886.39
EBIT Margin
2.10%6.78%10.19%12.02%13.05%11.50%
Effective Tax Rate
18.08%13.88%12.49%8.10%13.75%11.72%
Revenue as Reported
755.34857.55953.981,088969.84750.95
Advertising Expenses
-16.5743.4643.15--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.